Results 31 to 40 of about 46,564 (215)

Do we know properly young age breast cancer patients: a double centre study

Journal of Biochemical and Clinical Genetics, 2021
Background: According to American Cancer Society, an estimated 268,600 new cases of invasive breast cancer was diagnosed among women, and nearly 50,000 women were under age 50 years.
Hale Onder Yilmaz, Halil Tadkaynatan, Mustafa Gokoglu, Orkun Yilmaz, Gokmen Aktas   +4 more
doaj   +1 more source

Bayesian assessment of the prevalence of BRCA-associated breast cancer in Moscow

Alʹmanah Kliničeskoj Mediciny, 2020
Rationale: For many years, breast cancer has been leading in the cancer structure in women, accounting for 21% from the total number of newly diagnosed cases of malignancies in Russia. The literature on the prevalence of the BRCA-associated breast cancer
A. V. Viskovatykh
doaj   +1 more source

?????? ??????????????: ???????????????? ?????????????? ?????????????? ???? ???????????????? ???????????????? ???????????????????? ?????????????? ?? ?????????? BRCA1 ???? BRCA2 [PDF]

, 2019
?? ???????????? ???????????????????????????? ???????? ???????????????????? ?? ???????????????????? ?????????????? ???????????????????? ???????????????? ???????? ?????????????? (????) ???? ??????????????, ???? ?????????????????????? ?? ?????????????????? ?? ??????????-???????????????????? ???????????????????? ?????????? BRCA1/2, ?? ???? ?????????????????
openaire   +3 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

CLINICAL AND MORPHOLOGICAL FEATURES OF HEREDITARY OVARIAN CANCER

Сибирский онкологический журнал, 2017
Germ-line mutations in BRCA1 and BRCA2 genes are the most established risk factors for hereditary breast and ovarian cancers. The purpose of the study was to analyze BRCA1/2 testing in ovarian cancer patients. Materials and methods.
K. B. Kotiv, T. V. Gorodnova, A. O. Ivantsov, A. G. Iyevleva, S. N. Aleksakhina, G. M. Manichas, A. S. Lisyanskaya, R. P. Salomatov, M. S. Shushaniia, M. V. Borodenko, L. D. Roman, G. I. Mikhailiuk, O. N. Mikheeva, T. G. Grigorieva, I. V. Berlev, E. N. Imyanitov, A. P. Sokolenko   +16 more
doaj   +1 more source

Histopathological characterization of carcinoma breast with BRCA1/2 sequence variation in a Tertiary Care Center in Kerala, South India

Biomedical and Biotechnology Research Journal, 2022
Background: Hereditary breast cancers constitute around 5%–10% of all breast cancers. The most commonly mutated genes in hereditary breast and ovarian cancer syndrome are the BRCA1 and BRCA2 genes.
Reeba Mary Issac, Prema Saldanha, Jessy Mangalathu Mathai, Jency Mathews, Rebecca Mathews, Bindu Kumari, Tiju Chacko   +6 more
doaj   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Double heterozygous pathogenic variants in BRCA2 and CHEK2 in a girl with adrenocortical carcinoma [PDF]

Exploration of Endocrine and Metabolic Diseases
Pediatric adrenocortical tumors (pACTs) are rare endocrine neoplasms with variable prognosis, commonly associated with germline pathogenic variants (PVs) in the tumor suppressor gene TP53. Here, we report the case of a 3.1-year-old female presenting with
Victoria E. Fincke, Irmengard Sax, Marina Kunstreich, Monika M. Golas, Thomas G. Hofmann, Matthias Schlesner, Rainer Claus, Antje Redlich, Pascal D. Johann, Michaela Kuhlen   +9 more
doaj   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source